Overcoming Endocrine Resistance in Breast Cancer

Overview

Journal Cancer Cell

Publisher Cell Press

Specialty Oncology

Date 2020 Apr 15

PMID 32289273

Citations 356

Authors

Ariella B Hanker

Dhivya R Sudhan

Carlos L Arteaga

Affiliations

Soon will be listed here.

Abstract

Estrogen receptor-positive (ER) breast cancer is the most common breast cancer subtype. Treatment of ER breast cancer comprises interventions that suppress estrogen production and/or target the ER directly (overall labeled as endocrine therapy). While endocrine therapy has considerably reduced recurrence and mortality from breast cancer, de novo and acquired resistance to this treatment remains a major challenge. An increasing number of mechanisms of endocrine resistance have been reported, including somatic alterations, epigenetic changes, and changes in the tumor microenvironment. Here, we review recent advances in delineating mechanisms of resistance to endocrine therapies and potential strategies to overcome such resistance.

Citing Articles

Radiogenomic Landscape of Metastatic Endocrine-Positive Breast Cancer Resistant to Aromatase Inhibitors.

Khanyile R, Chipiti T, Hull R, Dlamini Z Cancers (Basel). 2025; 17(5).

PMID: 40075655 PMC: 11899325. DOI: 10.3390/cancers17050808.

Role of GPX3+ astrocytes in breast cancer brain metastasis activated by circulating tumor cell exosomes.

Huang G, Xu G, Cao Q, Li S, Li H, Zhang X NPJ Precis Oncol. 2025; 9(1):64.

PMID: 40055530 PMC: 11889224. DOI: 10.1038/s41698-025-00833-9.

Functional analysis of the effects of propofol on tamoxifen‑resistant breast cancer cells: Insights into transcriptional regulation.

Yin R, Gao J, Liu Y, Guo C Oncol Lett. 2025; 29(4):194.

PMID: 40041408 PMC: 11878209. DOI: 10.3892/ol.2025.14940.

Enhancer reprogramming: critical roles in cancer and promising therapeutic strategies.

Yang J, Zhou F, Luo X, Fang Y, Wang X, Liu X Cell Death Discov. 2025; 11(1):84.

PMID: 40032852 PMC: 11876437. DOI: 10.1038/s41420-025-02366-3.

Physical Health Decline After Chemotherapy or Endocrine Therapy in Breast Cancer Survivors.

Bodelon C, Masters M, Bloodworth D, Briggs P, Rees-Punia E, McCullough L JAMA Netw Open. 2025; 8(2):e2462365.

PMID: 40019757 PMC: 11871543. DOI: 10.1001/jamanetworkopen.2024.62365.

References

Fanning S, Greene G . Next-Generation ERα Inhibitors for Endocrine-Resistant ER+ Breast Cancer. Endocrinology. 2019; 160(4):759-769. DOI: 10.1210/en.2018-01095. View

Formisano L, Stauffer K, Young C, Bhola N, Guerrero-Zotano A, Jansen V . Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER Breast Cancer. Clin Cancer Res. 2017; 23(20):6138-6150. PMC: 6681458. DOI: 10.1158/1078-0432.CCR-17-1232. View

Hartmaier R, Trabucco S, Priedigkeit N, Chung J, Parachoniak C, Vanden Borre P . Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer. Ann Oncol. 2018; 29(4):872-880. PMC: 5913625. DOI: 10.1093/annonc/mdy025. View

Sansone P, Ceccarelli C, Berishaj M, Chang Q, Rajasekhar V, Perna F . Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer. Nat Commun. 2016; 7:10442. PMC: 4748123. DOI: 10.1038/ncomms10442. View

Shiino S, Kinoshita T, Yoshida M, Jimbo K, Asaga S, Takayama S . Prognostic Impact of Discordance in Hormone Receptor Status Between Primary and Recurrent Sites in Patients With Recurrent Breast Cancer. Clin Breast Cancer. 2016; 16(4):e133-40. DOI: 10.1016/j.clbc.2016.05.014. View

Jeselsohn R, Buchwalter G, De Angelis C, Brown M, Schiff R . ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer. Nat Rev Clin Oncol. 2015; 12(10):573-83. PMC: 4911210. DOI: 10.1038/nrclinonc.2015.117. View

Guerrero-Zotano A, Stricker T, Formisano L, Hutchinson K, Stover D, Lee K . ER Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors. Clin Cancer Res. 2018; 24(11):2517-2529. PMC: 6690756. DOI: 10.1158/1078-0432.CCR-17-2904. View

Zinger L, Merenbakh-Lamin K, Klein A, Elazar A, Journo S, Boldes T . Ligand-binding Domain-activating Mutations of ESR1 Rewire Cellular Metabolism of Breast Cancer Cells. Clin Cancer Res. 2019; 25(9):2900-2914. DOI: 10.1158/1078-0432.CCR-18-1505. View

Aggelis V, Johnston S . Advances in Endocrine-Based Therapies for Estrogen Receptor-Positive Metastatic Breast Cancer. Drugs. 2019; 79(17):1849-1866. DOI: 10.1007/s40265-019-01208-8. View

10.

Stone A, Zotenko E, Locke W, Korbie D, Millar E, Pidsley R . DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer. Nat Commun. 2015; 6:7758. PMC: 4510968. DOI: 10.1038/ncomms8758. View

11.

Fu X, Creighton C, Biswal N, Kumar V, Shea M, Herrera S . Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. Breast Cancer Res. 2014; 16(5):430. PMC: 4303114. DOI: 10.1186/s13058-014-0430-x. View

12.

Fu X, Jeselsohn R, Pereira R, Hollingsworth E, Creighton C, Li F . FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer. Proc Natl Acad Sci U S A. 2016; 113(43):E6600-E6609. PMC: 5087040. DOI: 10.1073/pnas.1612835113. View

13.

Rueda O, Sammut S, Seoane J, Chin S, Caswell-Jin J, Callari M . Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups. Nature. 2019; 567(7748):399-404. PMC: 6647838. DOI: 10.1038/s41586-019-1007-8. View

14.

Wittmann B, Sherk A, McDonnell D . Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators. Cancer Res. 2007; 67(19):9549-60. DOI: 10.1158/0008-5472.CAN-07-1590. View

15.

Chen H, Liu H, Qing G . Targeting oncogenic Myc as a strategy for cancer treatment. Signal Transduct Target Ther. 2018; 3:5. PMC: 5837124. DOI: 10.1038/s41392-018-0008-7. View

16.

Lombardo Y, Faronato M, Filipovic A, Vircillo V, Magnani L, Coombes R . Nicastrin and Notch4 drive endocrine therapy resistance and epithelial to mesenchymal transition in MCF7 breast cancer cells. Breast Cancer Res. 2014; 16(3):R62. PMC: 4095694. DOI: 10.1186/bcr3675. View

17.

Desmedt C, Zoppoli G, Gundem G, Pruneri G, Larsimont D, Fornili M . Genomic Characterization of Primary Invasive Lobular Breast Cancer. J Clin Oncol. 2016; 34(16):1872-81. DOI: 10.1200/JCO.2015.64.0334. View

18.

Guan J, Zhou W, Hafner M, Blake R, Chalouni C, Chen I . Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility. Cell. 2019; 178(4):949-963.e18. DOI: 10.1016/j.cell.2019.06.026. View

19.

Tria G, Abrams T, Baird J, Burks H, Firestone B, Gaither L . Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer. J Med Chem. 2018; 61(7):2837-2864. DOI: 10.1021/acs.jmedchem.7b01682. View

20.

Bardia A, Kaklamani V, Wilks S, Weise A, Richards D, Harb W . Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer. J Clin Oncol. 2021; 39(12):1360-1370. PMC: 8078341. DOI: 10.1200/JCO.20.02272. View